{"product_id":"drug-treatment-of-sleep-disorders-milestones-in-drug-therapy","title":"Drug Treatment of Sleep Disorders (Milestones in Drug Therapy)","description":"\u003cp\u003e\u003cstrong\u003eBook info:\u003c\/strong\u003e Drug Treatment of Sleep Disorders (Milestones in Drug Therapy) (Hardcover, 305 pages) – Springer, 2014. Language: English.\u003c\/p\u003e\n \u003cp\u003eFollowing reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.\u003c\/p\u003e  \n\n                                         Editorial Reviews                   Review   \u003cp\u003e“This book explores major breakthroughs in the drug treatment of sleep disorders. … The intended audience is scientists, clinicians, and drug developers. … With its specific aim of providing an extensive update on drug treatment for sleep disorders, this book is helpful contribution to sleep medicine.” (M. Isabel L. Crisostomo, Doody’s Book Reviews, July, 2015)\u003c\/p\u003e           From the Back Cover   \u003cp\u003eFollowing reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.\u003c\/p\u003e                                           ","brand":"Antonio Guglietta","offers":[{"title":"Default Title","offer_id":46070518317290,"sku":"9783319115139","price":107.52,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0714\/5301\/6298\/files\/614JwPVmDlL._SL1500.jpg?v=1781267466","url":"https:\/\/textbookme.store\/products\/drug-treatment-of-sleep-disorders-milestones-in-drug-therapy","provider":"TextbookMe","version":"1.0","type":"link"}